

## RESTORING LIVER HEALTH.

*Promethera<sup>®</sup>'s mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide both immunomodulatory and anti-fibrotic effects in the liver.*

### HEPASTEM™ FOR LIVER RESCUE THERAPY

The company's lead clinical program is derived from a patented allogeneic liver cell platform called HepaStem™. Currently in a Phase 2b clinical trial to treat patients with Acute-on-Chronic Liver Failure (ACLF), the program has the potential to target other severe and more prevalent chronic liver diseases such as Non-Alcoholic Steatohepatitis (NASH). Promethera<sup>®</sup> has developed its cell therapy technologies by using allogeneic stem and progenitor liver cells. These are isolated, purified and expanded from healthy human livers unsuitable for transplantation. The process for developing these cells into a medical treatment enables the delivery of the cells to patients directly at point of care.

### TNF-R1 INHIBITION - A COMPLEMENTARY THERAPEUTIC STRATEGY

Promethera<sup>®</sup> has strengthened its development portfolio in 2018 through the acquisition of the Swiss biopharmaceutical company Baliopharm AG. As part of the transaction, Promethera<sup>®</sup> added a complimentary therapeutic strategy to its portfolio of severe liver disease medicines by selectively targeting the TNF-alpha receptor 1 (TNF-R1) and is currently preclinically

developing the novel antibody-based monovalent drug candidate Atrosimab towards clinical trials in NASH/ Fibrosis indication.


### WELL POSITIONED FOR CELL THERAPY EXCELLENCE

The company was founded in 2009 by Etienne Sokal, Promethera<sup>®</sup> Biosciences' Group CMO and Professor of medicine at the Université Catholique de Louvain. It is located within the Walloon healthcare cluster, Biowin, in Belgium. The Walloon region is internationally known for excellence in cell therapy research and is actively supporting Promethera.

In 2016, Promethera<sup>®</sup> acquired Cytonet's key assets, including its US facility based in Durham, North Carolina at the heart of the Research Triangle Park (RTP), an important center for medical research and innovation in the USA. The acquisition brought a state-of-the-art production facility in the US as well as a powerful network for sourcing ethically-donated human livers from US OPO's (Organ Procurement Organizations) to complement the cGMP facilities and tissue procurement centers in Belgium / UE along with additional experienced leadership and talents.

### PRODUCT PIPELINE


Promethera<sup>®</sup> Biosciences' product portfolio includes potential treatments for liver diseases such as ACLF, NASH & Fibrosis



\* Pivotal Phase 2b Study

## FULLY INTEGRATED PRODUCT SOURCING, PRODUCTION & SUPPLY CHAIN


Mastering the supply chain for an off-the-shelf allogeneic cell therapy product



## FINANCIAL INFORMATION

Promethera® has garnered the support of blue chip venture and corporate venture funds including strategic Japanese and Korean investors, further enabling Promethera's vision of treating patients worldwide.

EUR 120M raised in equity and semi-equity since inception, not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.



## MANAGEMENT

Promethera® has attracted an experienced management team of international experts based at our facilities in Belgium, the US, Japan and Switzerland.

- **JOHN TCHELINGERIAN**, PhD - President & CEO
- **ETIENNE SOKAL**, MD, PhD - Founder & Group CMO
- **BERTRAND LELLOUCHE**, MBA - Group CFO
- **NATHALIE BELMONTE**, PhD - COO
- **LUC OTTEN**, MD, PhD - CSO
- **PAUL SMITH** - VP of Regulatory Affairs
- **NATHALIE CLERGET**, PHD - VP of Clinical Development
- **THOMAS VAN LOOCK** - Global VP QA & QP
- **DAVID BREMS** - VP Finance
- **MICHIHIRO MAEDA** - General Manager Japan Branch

## BOARD OF DIRECTORS

Promethera® is strategically advised by a distinguished international board of directors to drive us towards our goal of being the global leader in innovative cell therapies for liver diseases.

- **CHARLES DIMMLER III**, PhD - Chairman of the Board
- **JOHN TCHELINGERIAN**, PhD - Director
- **ETIENNE SOKAL**, MD, PhD - Director
- **TAJIO ENOKI** - Director
- **REIKO NAMIKAWA**, MD, PhD - Director
- **MASAKI DOI**, PhD - Director
- **EDWARD HAACK** - Director

[promethera.com](http://promethera.com)

**PROMETHERA Biosciences S.A./N.V. (Head Office)**  
Watson & Crick Hill | Rue Granbonpré, 11  
1435 Mont-Saint-Guibert, Belgium  
[info@promethera.com](mailto:info@promethera.com)

**PROMETHERA Biosciences Japan Branch (Japan Operations)**  
Ueno Building 5F | 1-9-10 Nihonbashi-Horidomecho  
Chuo-ku, Tokyo, 103-0012, Japan  
[info.japan@promethera.com](mailto:info.japan@promethera.com)

**PROMETHERA Biosciences LLC (US Operations)**  
801 Capitola Drive | Suite 8  
Durham, NC 27713, U.S.A.  
[usteam@promethera.com](mailto:usteam@promethera.com)

**Baliopharm AG - part of the Promethera Group**  
Stänzlergasse 4  
CH-4051 Basel, Switzerland  
[info@promethera.com](mailto:info@promethera.com)

**John Tchelingerian, PhD**, President & CEO  
[John.Tchelingerian@promethera.com](mailto:John.Tchelingerian@promethera.com)

**Bertrand Lellouche, MBA**, Group CFO  
[Bertrand.Lellouche@promethera.com](mailto:Bertrand.Lellouche@promethera.com)